A clinical trial is only as valuable as the reliability of its results. ObvioHealth’s DCT experts know how to design your trial to recruit and train the optimal cohort and root out statistical “noise”—so you get the robust evidence you need.
Factors most likely to drive poor results are flawed study design, wrong choice of endpoint, and inadequate sample size*
*See analysis of 640 Phase III trials by Hwang et. al.
The ObvioHealth team is made up of seasoned professionals who have deep clinical, data science, and technology expertise. Benefit from our track record of designing successful decentralized clinical trials through some or all of the following key steps.
Ensuring more precise and efficient identification of recruitment targets.
Merging clinical science with data science to determine the best endpoints and outcomes for a given TA and protocol.
Providing recommendations for instruments that are technically and clinically valid as well as user-friendly.
Multi-vital devices can make life easier for patients. But, the more things get measured, the more the quality of the data tends to suffer. Instrument selection must determine the right balance between these sometimes conflicting criteria.
Reducing the bias, errors, and variability inherent in self-reporting and rater scoring.
Validating novel instruments tailored to your trial to provide more nuanced and accurate measurements of outcomes.
ObvioHealth launched one of the first-ever DCT platforms with a mobile app in 2017. Today, we’re a global industry leader delivering DCTs that generate stronger evidence.
During peak COVID-19, ObvioHealth worked with Red Hill Biopharma to evaluate the safety of a new treatment for viral symptoms. ObvioHealth’s consulting team was asked to develop an ePRO tool to measure signs and symptoms of the virus remotely and thus minimize the risk of contagion from hospital visits. Successful study endpoints developed and validated through concept elicitation, cognitive debriefing, and usability testing led the sponsor to proceed to Phase III preparations.